Tech Company Financing Transactions
Psylo Funding Round
Tenmile, Gaingels and Mystic Ventures joined a $8 million Seed funding round for Psylo. The financing round was announced on 6/3/2024.
Transaction Overview
Company Name
Announced On
6/3/2024
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the advancement of PSYLO-100X, its flagship non-hallucinogenic 5-HT2A agonist, for the treatment of depression and other mental health disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
L2 11-31 York Street
Sydney, New South Wales, 2000
Australia
Sydney, New South Wales, 2000
Australia
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
We develop next-generation therapeutics, inspired by psychedelics from nature. Our mission is to extend the healing potential of psychedelics to a broader patient population. Our objective is to develop widely-accessible medications that offer an improved treatment alternative to current SSRIs, using psychedelic molecules as the starting point.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Ismin
Chief Marketing Officer
Dilara Bahceci
Chief Scientific Officer
Sam Banister
Vice President
Jianmin Duan
Vice President
Donald Gehlert
VP - Administration
Krista Licata
Browse more venture capital transactions:
Prev: 6/3/2024: Caju AI venture capital transaction
Next: 6/3/2024: Punto Health venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs